Nevro Corp (NVRO) VP Michael Enxing Sells 1,500 Shares of Stock
Nevro Corp (NASDAQ:NVRO) VP Michael Enxing sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, October 4th. The stock was sold at an average price of $99.31, for a total value of $148,965.00. Following the sale, the vice president now directly owns 39,463 shares in the company, valued at $3,919,070.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Michael Enxing also recently made the following trade(s):
- On Thursday, August 4th, Michael Enxing sold 1,500 shares of Nevro Corp stock. The stock was sold at an average price of $82.06, for a total value of $123,090.00.
Nevro Corp (NASDAQ:NVRO) opened at 94.15 on Monday. Nevro Corp has a 52 week low of $36.51 and a 52 week high of $106.93. The company has a 50-day moving average price of $97.65 and a 200 day moving average price of $78.56. The company’s market cap is $2.68 billion.
Nevro Corp (NASDAQ:NVRO) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.31) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.16. The company earned $55.40 million during the quarter, compared to analysts’ expectations of $45.11 million. The firm’s revenue was up 385.5% on a year-over-year basis. On average, equities research analysts forecast that Nevro Corp will post ($1.42) EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Sei Investments Co. raised its position in Nevro Corp by 40.0% in the second quarter. Sei Investments Co. now owns 1,620 shares of the company’s stock worth $119,000 after buying an additional 463 shares during the period. Fortaleza Asset Management Inc. acquired a new position in Nevro Corp during the second quarter worth $125,000. BlackRock Inc. raised its position in Nevro Corp by 130.1% in the second quarter. BlackRock Inc. now owns 2,487 shares of the company’s stock worth $183,000 after buying an additional 1,406 shares during the period. BNP Paribas Arbitrage SA raised its position in Nevro Corp by 110.8% in the third quarter. BNP Paribas Arbitrage SA now owns 1,977 shares of the company’s stock worth $206,000 after buying an additional 1,039 shares during the period. Finally, Numeric Investors LLC acquired a new position in Nevro Corp during the second quarter worth $207,000.
Several equities research analysts have weighed in on NVRO shares. Zacks Investment Research raised Nevro Corp from a “hold” rating to a “buy” rating and set a $110.00 price objective on the stock in a research note on Wednesday, October 5th. Morgan Stanley reaffirmed a “buy” rating and set a $86.00 target price on shares of Nevro Corp in a research note on Wednesday, June 29th. Wells Fargo & Co. assumed coverage on Nevro Corp in a research note on Tuesday, July 12th. They set an “outperform” rating on the stock. William Blair assumed coverage on Nevro Corp in a research note on Tuesday, July 19th. They set an “outperform” rating on the stock. Finally, JMP Securities upped their target price on Nevro Corp from $90.00 to $110.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 9th. Eleven equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $104.00.
About Nevro Corp
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.
Receive News & Stock Ratings for Nevro Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp and related stocks with our FREE daily email newsletter.